Product
Quadrivalent influenza vaccine
Aliases
0.25ml Quadrivalent influenza vaccine, Fluarix Tetra / Fluarix® Quadrivalent, Quadrivalent influenza vaccine(0.25ml), Quadrivalent influenza vaccine(0.5ml) (2 other aliases)
9 clinical trials
6 indications
Indication
InfluenzaIndication
Influenza ImmunizationIndication
Multiple SclerosisIndication
HumanIndication
VaccinesIndication
Seasonal InfluenzaClinical trial
Immunogenicity and Safety of a Quadrivalent Influenza Vaccine in Participants Aged Above 3 YearsStatus: Completed, Estimated PCD: 2019-10-08
Clinical trial
Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine Compared With Egg-Based Standard-Dose Quadrivalent Influenza Vaccine in Children 3 to 8 Years of Age.Status: Terminated, Estimated PCD: 2023-10-03
Clinical trial
An Open-label Multicenter Study to Assess Response to Influenza Vaccine in Participants With Multiple Sclerosis Treated With Ofatumumab 20 mg SubcutaneouslyStatus: Completed, Estimated PCD: 2023-07-06
Clinical trial
Immunogenicity and Safety of Quadrivalent Influenza Vaccine In 6 to 35 Months Population: a Randomized, Double-blind, Parallel-group Ⅱ Phase of Clinical TrialsStatus: Completed, Estimated PCD: 2021-09-14
Clinical trial
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDERStatus: Completed, Estimated PCD: 2024-03-12
Clinical trial
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, DOSE-RANGING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MODIFIED RNA VACCINE CANDIDATES AGAINST PANDEMIC INFLUENZA IN HEALTHY INDIVIDUALS 18 THROUGH 49 YEARS OF AGEStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
An Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35monthsStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
An Open Phase I and Randomized, Double-blind, Controlled Phase III Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35months.Status: Recruiting, Estimated PCD: 2023-12-20
Clinical trial
A PHASE 1, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF SELF-AMPLIFYING RNA VACCINE PREPARATIONS AGAINST INFLUENZA IN HEALTHY INDIVIDUALSStatus: Completed, Estimated PCD: 2023-08-04